Uniunea Europeană - română - EMA (European Medicines Agency)

merck sharp & dohme b.v. - doravirine - infecții cu hiv - antivirale pentru uz sistemic - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

acs dobfar s.p.a. - italia - meropenemum - pulb. pt. sol. inj./perf. - 1000mg - alte antibiotice betalactamice carbapeneme

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

acs dobfar s.p.a. - italia - meropenemum - pulb. pt. sol. inj./perf. - 500mg - alte antibiotice betalactamice carbapeneme

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

getz pharma(pvt) ltd - daclatasvirum - comprimate filmate - 60 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

rotapharm limited - daclatasvirum - comprimate filmate - 60 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

novartis pharma ag - imatinibum - comprimate filmate - 100 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

novartis pharma ag - imatinibum - comprimate filmate - 400 mg

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

s&d pharma cz, spol. s.r.o. - republica ceha - valganciclovirum - compr. film. - 450mg - antivirale cu actiune directa nucleozide & nucleotide excl inhib. si reverstranscriptei

Uniunea Europeană - română - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - sânii neoplasme - agenți antineoplazici - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.